Syndax Pharmaceuticals, Inc.
At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. Our pipeline includes revumenib, a highly selective inhibitor of the Menin–KMT2A binding interaction, in development for the treatment of patients with KMT2Ar and NPM1m acute leukemias. Syndax is also developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, for chronic graft-versus-host disease.